checkAd

     2410  0 Kommentare Medical Breakthroughs Propel Psilocybin Closer to Legalization - Seite 4

    Better Plant Sciences Inc. (CSE:PLNT) (OTCQB:VEGGF) reported last year that its majority owned subsidiary NeonMind Biosciences ("NeonMind") has entered into a definitive agreement with Psygen Labs Inc. ("Psygen") for the supply of psilocybin for NeonMind's planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety. The agreement was signed on September 28th, 2020. "Psilocybin is known to activate serotonin receptors," says Dr. William Panenka, lead scientific advisor to NeonMind. "As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings."

    Codebase Ventures (CSE:CODE) (OTCQB:BKLLF) announced last year that its subsidiary, Titan Shrooms and Psychedelics has signed a letter of intent to form a joint venture with arms-length mushroom biotech company Mycology Ventures. The resulting joint venture would see Titan holding a 70% interest. Mycology's leadership brings extensive experience and combined networks from the cannabis, CBD and mushroom sectors, in addition to medical and academic research fields, which will be deployed to identify and secure early stage investment opportunities to benefit CODE shareholders. "The U.S., along with many other countries, is illustrative of the dangers of opioid and anti-depressant pharmacology," said Mr. George Tsafalas, Code CEO. "The resulting openness to viable alternatives, including psilocybin, by regulatory bodies and major research institutions is a strong indicator of the potential for this sector. As it relates to psilocybin for depression, the FDA has granted a 'breakthrough therapy' designation to advance legal clinical trials, which indicates that we are at the start of pioneering effort to reshape medicine as it applies to mental illness, pain management and addiction."

    Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

    Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

    Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

    Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

    About FinancialBuzz.com 

    Seite 4 von 6



    Diskutieren Sie über die enthaltenen Werte



    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Medical Breakthroughs Propel Psilocybin Closer to Legalization - Seite 4 - FinancialBuzz.com News Commentary NEW YORK, March 1, 2021 /PRNewswire/ - The psychedelics market is currently navigating a similar legal situation to the one the cannabis market found itself in for many years. Psychedelics are not legal for …